載入中
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$52.45
−US$1.36 · -2.53%
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
收盤時
US$52.45
−US$1.36 · -2.53%
盤後
US$52.45
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日內區間
目前US$52.45
52週區間
目前US$52.45
盤中時間採用ET。市場資料可能有所延遲。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日內區間
目前US$52.45
52週區間
目前US$52.45
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$53.20
上漲空間 1.43%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2791.36萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2657.02萬0.03%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1087.54萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO934.12萬0.07%139.17億 USD0.24%US$353.71-0.86%
Schwab U.S. Small-Cap ETFSCHA571.86萬0.03%218.24億 USD0.03%US$32.66-0.40%
Vanguard Russell 2000 ETFVTWO536.95萬0.03%180億 USD0.06%US$112.27-0.35%
iShares U.S. Medical Devices ETFIHI531.99萬0.15%35.74億 USD0.37%US$52.79+2.03%
Invesco Dorsey Wright Healthcare Momentum ETFPTH333.32萬1.16%2.87億 USD0.74%US$58.3797-0.65%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares U.S. Medical Devices ETFIHIInvesco Dorsey Wright Healthcare Momentum ETFPTHAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
